Comparing Arsenic-Containing Qinghuang Powder and Low-Intensity Chemotherapy in Elderly Patients with Acute Myeloid Leukemia

被引：0
|
作者：
Yu-he Wu
Hai-yan Xiao
Ri-cheng Quan
Xu-dong Tang
Wei-yi Liu
Yan Lyu
Zhuo Chen
Chi Liu
Xiao-mei Hu
机构：
[1] China Academy of Chinese Medical Sciences,Department of Hematology, Xiyuan Hospital
[2] China Academy of Chinese Medical Sciences,Graduate School
来源：
Chinese Journal of Integrative Medicine | 2023年 / 29卷
关键词：
acute myeloid leukemia; elderly; Qinghuang Powder; low-intensity chemotherapy; Chinese medicine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：832 / 837
页数：5
相关论文
共 50 条
  • [21] Infections in patients with acute myeloid leukemia treated with low-intensity therapeutic regimens: Risk factors and efficacy of antibiotic prophylaxis
    Bainschab, Antonia
    Quehenberger, Franz
    Greinix, Hildegard T.
    Krause, Robert
    Woelfer, Albert
    Sill, Heinz
    Zebisch, Armin
    LEUKEMIA RESEARCH, 2016, 42 : 47 - 51
  • [22] Arsenic Trioxide and Low-dose Cytarabine in Older Patients With Untreated Acute Myeloid Leukemia, Excluding Acute Promyelocytic Leukemia
    Roboz, Gail J.
    Ritchie, Ellen K.
    Curcio, Tania
    Provenzano, Juliette
    Carlin, Rebecca
    Samuel, Michael
    Wittenberg, Beth
    Mazumdar, Madhu
    Christos, Paul J.
    Mathew, Susan
    Allen-Bard, Sandra
    Feldman, Eric J.
    CANCER, 2008, 113 (09) : 2504 - 2511
  • [23] Patient characteristics, treatment patterns, and mortality in elderly patients newly diagnosed with acute myeloid leukemia meeting ineligibility criteria for high intensity chemotherapy
    Li, Shuling
    Ji, Yuanyuan
    Peng, Yi
    Kota, Vamsi
    Kim, Christopher
    LEUKEMIA & LYMPHOMA, 2022, 63 (01) : 131 - 141
  • [24] An extensive pharmacokinetic, metabolic and toxicological review of elderly patients under intensive chemotherapy for acute myeloid leukemia
    Kaur, Imit
    Constance, Jonathan E.
    Kosak, Ken M.
    Spigarelli, Michael G.
    Sherwin, Catherine M. T.
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2015, 11 (01) : 53 - 65
  • [25] Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia
    Etienne, Anne
    Esterni, Benjamin
    Charbonnier, Aude
    Mozziconacci, Marie-Joelle
    Arnoulet, Christine
    Coso, Diane
    Puig, Brigitte
    Gastaut, Jean-Albert
    Maraninchi, Dominique
    Vey, Norbert
    CANCER, 2007, 109 (07) : 1376 - 1383
  • [26] Intensity of chemotherapy for the initial management of newly diagnosed acute myeloid leukemia in older patients
    Michalski, Joel M.
    Lyden, Elizabeth R.
    Lee, Andrea J.
    Al-Kadhimi, Zaid S.
    Maness, Lori J.
    Gundabolu, Krishna
    Bhatt, Vijaya Raj
    FUTURE ONCOLOGY, 2019, 15 (17) : 1989 - 1995
  • [27] Standard induction chemotherapy followed by attenuated consolidation in elderly patients with acute myeloid leukemia
    Je-Hwan Lee
    Seong-Jun Choi
    Jung-Hee Lee
    Jae-Hoo Park
    Hawk Kim
    Young-Don Joo
    Won Sik Lee
    Dae Young Zang
    Hyo Jung Kim
    Kyoo-Hyung Lee
    Annals of Hematology, 2006, 85 : 357 - 365
  • [28] Oral induction and consolidation chemotherapy with idarubicin and etoposide in elderly patients with acute myeloid leukemia
    Oriol, A
    Ribera, JM
    Brunet, S
    Esteve, J
    Bueno, J
    Llorente, A
    HAEMATOLOGICA, 2003, 88 (02) : 229 - 230
  • [29] Standard induction chemotherapy followed by attenuated consolidation in elderly patients with acute myeloid leukemia
    Lee, JH
    Choi, SJ
    Lee, JH
    Park, JH
    Kim, H
    Joo, YD
    Lee, W
    Zang, D
    Kim, HJ
    Lee, KH
    ANNALS OF HEMATOLOGY, 2006, 85 (06) : 357 - 365
  • [30] Selection of Elderly Acute Myeloid Leukemia Patients for Intensive Chemotherapy: Effectiveness of Intensive Chemotherapy and Subgroup Analysis
    Kim, Dae Sik
    Kang, Ka Won
    Yu, Eun Sang
    Kim, Hong Jun
    Kim, Jung Sun
    Lee, Se Ryeon
    Park, Yong
    Sung, Hwa Jung
    Yoon, Soo Young
    Choi, Chul Won
    Kim, Byung Soo
    ACTA HAEMATOLOGICA, 2015, 133 (03) : 300 - 309
12345